China based MEDx (Suzhou) Translational Medicine, and Singapore-based Lucence - a leading genomic medicine company - have announced an agreement to pursue a strategic partnership in China to co-develop cancer-care tests that would benefit patients and pharmaceutical companies.

By melding MEDx’s industry-leading biomarker discovery, cancer molecular diagnostics, high-throughput sequencing and bioinformatics platforms; with Lucence’s proprietary technology platform that identifies PD-L1 rearrangement, as well as multiplex immunofluorescence that allows better prediction of anti-PD1/PD-L1 treatment outcomes, this partnership is poised to go from strength to strength in this sunrise industry of precision medicine.

“Immunotherapy is becoming more and more popular for drug development and personalized medicine in China. A good companion diagnosis is needed to complement immunotherapy. We believe through this strategic partnership with Lucence, we will achieve better outcomes for cancer diagnosis and treatment selection for cancer patients,” said Dr. Nick Zhang, Chairman and CEO of MEDx (Suzhou) Translational Medicine.

“The complementary strengths of Lucence and MEDx to co-develop cancer-care tests in China will ensure that patients have access to non-invasive, cost-effective, faster and better diagnosis. With our steadfast focus on reducing avoidable cancer deaths, coupled with MEDx’s deep experience and wide presence in China, we are confident that this partnership will drive better cancer care in China,” said Dr. Min-Han Tan, Founder and CEO of Lucence.